Summary
This study is researching an experimental drug called REGN3767, also known as fianlimab
(R3767), when combined with another medication called cemiplimab (each individually
called a "study drug" or called "study drugs" when combined) compared with an approved
medication called pembrolizumab. These types of study drugs are collectively known as
immune checkpoint inhibitors. The study is focused on participants with a type of skin
cancer known as melanoma.
The objective of this study is to see if the combination of fianlimab and cemiplimab is
an effective treatment compared to pembrolizumab as peri-operative therapy in
participants with high-risk melanoma.
The study is looking at several other research questions, including:
- What side effects may happen from receiving the study drug(s).
- How much study drug(s) is in the blood at different times.
- Whether the body makes antibodies against the study drug(s) (which could make the
drug less effective or could lead to side effects). Antibodies are proteins that are
naturally found in the blood stream that fight infections.
- How administering the study drugs might improve quality of life.